AI and Nanomedicine Enable Early Disease Detection via Blood Biomarkers
June 23, 2025
Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- Published in the Chemical Engineering Journal on April 1, 2025.
- Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.